Everest Medicines Reaffirms Revenue Guidance for the Year 2023 and 2024
The company is reaffirming revenue guidance for 2024 of RMB 700 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.05 HKD | +1.15% | -4.34% | +5.50% |
May. 14 | Calliditas Therapeutics Partner Offers Nefecon in China; Shares Rise | MT |
May. 14 | Everest Medicines Announces Commercial Launch and First Prescription for NEFECON in Mainland China | CI |
1st Jan change | Capi. | |
---|---|---|
+5.50% | 903M | |
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |